Drug Combination Details
| General Information of the Combination (ID: C05101) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | GM-CSF Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | JAK-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | PML | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RARA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| UF-1 | CVCL_0567 | Acute promyelocytic leukemia | Homo sapiens | |||
| In-vivo Model | Human GM-CSF-producing trans genic SCID (hGMTgSCID) mice were pretreated with 3 Gy of total body irradiation and then inoculated subcutaneously with UF-1 cells (1 * 107 cells) in their logarithmic growth phase. | |||||
| Experimental
Result(s) |
A combination of As2O3 and GM-CSF induces differentiation of APL cells both in vitro and in vivo. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. Leukemia. 2001 Aug;15(8):1176-84. | |||
